Are you attending the #BIO2024 International Convention? Today our CEO, Dan Passeri, is participating on the panel “What’s Nex-T: Innovator Roundtable on T Cell Therapies in Oncology” to discuss the future of T cell directed approaches in cancer. For more: bit.ly/3X7zau1

#ICYMI Nataliya Uboha, MD, PhD, Assoc. Prof., University of Wisconsin Carbone Cancer Center & Steven Margossian, MD, PhD, Medical Director at $CUE discussed updated Ph1 data on our WT1-specific cancer asset at the ASCO Annual Meeting. Poster here: bit.ly/3KrL9Lw #ASCO24

At Cue Biopharma, we aim to restore immune balance to address cancer and #autoimmune disease through our therapeutic Immuno-STAT™ platform and approach. Learn more about our autoimmune biologics here: bit.ly/3yUHZx7

CUE Biopharma’s Immuno-STAT™ platform & biologics are designed to mitigate the most challenging problems in cancer #immunotherapy: lack of consistent efficacy, off-tumor toxicities and cost of production. How? By activating tumor-specific T cells. Learn more in this video.

If you’re interested in hearing insights on what’s next for T-cell therapies in oncology, check out FiercePharma’s Angus Liu moderate a discussion of 4 experts, including U.S. FDA’s Dr. Lola Fashoyin & our CEO Dan Passeri on LifeSci Communications’ panel at #BIO24: bit.ly/4cCqUXk

Our Immuno-STAT™ platform leverages the body’s immune memory to deplete autoreactive B cells to address #autoimmune and inflammatory diseases. Watch the animation and learn how our innovative approach works via the newly deployed CUE-500 series.

In the latest issue of Drug Discovery World, our CEO Dan Passeri and fellow industry experts discuss the global innovation and opportunity in #cancer research. Read on the promise of cytokine-based drugs, our Immuno-STAT™ platform & pipeline, and more (pg.42): bit.ly/4cHqZcf

We are harnessing the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Check out our advancing pipeline of targeted interleukin 2 (IL-2) based #immunotherapies to learn more: bit.ly/3LrpFie

In this pharmaphorum interview with Jonah Comstock, our CMO, Matteo Levisetti, M.D., discusses our recent #ASCO data and shares insights on our oncology programs, cancer immunotherapy and our differentiated Immuno-STAT™ platform potential. Access here: bit.ly/4bW994M

In a Q&A with Drug Target Review, our CSO Anish Suri, Ph. D., explores Cue Biopharma’s approach to translate nature’s cues into breakthrough #immunotherapies for autoimmune diseases and cancer. Read here: bit.ly/46Kt31L

#SavetheDate for our upcoming #BusinessUpdate call on Monday, August 19 at 4:30 pm EDT. For more information and to access the live webcast link, click here: bit.ly/4fFzQ0B $CUE

Today, we announced our second quarter financial results and updated business highlights. Read our #PressRelease to learn more: bit.ly/3yVX41P $CUE

#ICYMI, we provided a business overview of our recent restructuring and near-term strategic prioritization objectives. Click here for the full webcast replay: bit.ly/4dUTnIH

We look forward to the 15th Annual World Bispecific Summit, where our Director of Translational Pharmacology, Natasha Girgis, will present on Immuno-STATs™: our novel class of T cell engagers for #AutoimmuneDisease. Learn more here: bit.ly/3AG5lHO

Members of management will deliver two presentations at this year’s The Promise of #Interleukin-2 Therapy Conference in Paris, France. Learn more here: bit.ly/3X9XgTo

We are pleased to welcome industry veteran Lucinda Warren as chief business officer (CBO). Ms. Warren holds over 30 years of global industry experience and will play a pivotal role in advancing our core corporate objectives. Learn more here: bit.ly/3MFWbxP

Are you attending this year’s LSX USA Congress? Our CEO, Dan Passeri, will join fellow industry leaders on the panel “Funding Biotech Innovation and Scaling Up” to discuss evolving operating models, delivering stakeholder value & more. For details: bit.ly/3XdisYC #LSXUSA

Yesterday, our CEO, Dan Passeri, joined other biotech leaders in a panel discussion at the LSX USA Congress to discuss “Funding Biotech Innovation and Scaling Up”. Many thanks to the moderator Kyle DiLella, from Citi, and all other panelists for an insightful discussion. #LSXUSA

Yesterday, the #Cuemittee participated in a volunteer event at Mass Audubon in Mattapan that included painting the organization’s community center. Thanks to our team of volunteers for taking time out to give back to the local #Boston community!

Our newly deployed CUE-500 series leverages the body’s immune memory to deplete autoreactive B cells to address #autoimmune and inflammatory diseases. Learn more about our innovative approach and potential autoimmune opportunity here: bit.ly/3yUHZx7